Slope and CellCarta Join Forces to Enhance Clinical Logistics
Leading Biospecimen Lifecycle Management Platform and Global CRO Formalize Collaboration Following Successful Pilot
Slope, recognized as the only end-to-end, vendor-agnostic platform dedicated to managing biospecimens and lab kits, alongside CellCarta, a prominent global contract research organization (CRO), has taken a significant step forward by announcing a formal collaboration regarding their Kit Inventory Portal (KIP). This important development follows a successful pilot program, establishing Slope's platform as a vital component of CellCarta's logistics offerings for both new and ongoing client studies.
Streamlining Clinical Logistics
This collaboration significantly enhances the infrastructure that supports CellCarta's broad spectrum of pharmaceutical clients. It provides a streamlined approach to sample collection kit ordering, management of inventory, and replenishment workflows. The innovative solution is designed to be user-friendly for all sites involved and has proven effective in reducing kit waste by as much as 71%. Thanks to Slope’s platform, clinical sites can now directly place kit orders, benefiting from automated resupply options and customizable approval processes. Orders flow directly into CellCarta's ERP system, while shipment tracking updates automatically synchronize with site workspaces, offering real-time insights into inventory levels and simplifying how sites manage their supplies.
Expert Insights on Partnership Value
Ben Carmel, Chief Revenue Officer at Slope, stated, "This transition from pilot program to a long-term collaborative relationship confirms the operational benefits Slope brings to CROs, clinical sites, and their sponsors. We're witnessing a surge in momentum across the CRO landscape, as organizations increasingly recognize that modern biospecimen logistics infrastructure is essential for maintaining competitiveness and fulfilling sponsor and site expectations."
Transforming Clinical Logistics into a Competitive Advantage
According to Kristien Verhoeven, Senior Vice-President of Histopathology, Genomics and Logistics at CellCarta, "By standardizing the Kit Inventory Portal across our portfolio, we've shown how effective technology can turn clinical logistics from an industry-wide challenge into an advantageous tool that eases site burdens, enhances stakeholder visibility, and reduces wasteful lab kit expenses."
This partnership between Slope and CellCarta showcases a strategic model for how pilot programs can evolve into long-lasting alliances. This collaboration highlights how technology can deliver significant operational enhancements, allowing stakeholders to concentrate their efforts on advancing clinical science rather than navigating through complex operational processes.
The Benefits of a Robust Partnership
Through the Slope-CellCarta agreement, both companies are setting a benchmark for the industry. By minimizing manual coordination, bolstering inventory visibility, and improving research site experiences, this collaboration allows all involved to prioritize their resources toward the advancement of clinical research and science. The reduction of operational inefficiencies greatly contributes to the overall success and cost-effectiveness of clinical trials.
Understanding CellCarta's Role in the Partnership
CellCarta serves a critical function as a prominent global contract research organization in the biopharmaceutical sphere. With its CAP accreditations and CLIA certifications, the company provides advanced assay services and a completely integrated quality management system across several countries, including Canada and the United States. With a focus on delivering comprehensive biomarker testing services, CellCarta supports top pharmaceutical companies by offering tailored solutions throughout the drug discovery journey—from early research stages through to late-stage clinical trials.
The Unique Position of Slope
Slope distinguishes itself as the unique end-to-end, vendor-neutral platform designed for effective management of biospecimens and clinical inventory across the comprehensive clinical research ecosystem. Recognized for its reliability, Slope is trusted by over 2,200 sites in more than 23 countries. The platform is appreciated for delivering significant results, achieving an average reduction of 71% in lab kit waste, achieving 98% site adoption on sponsor-contracted trials, and significantly reducing lab queries by up to 98%. By integrating every aspect of the biospecimen lifecycle—from logistics and sampling to processing, storage, shipping, and data exchange—it effectively eliminates inefficiencies, ensuring smoother and more cost-effective trials.
Through this strategic partnership, both Slope and CellCarta aim to further enhance their offerings and capabilities, ensuring that they remain at the forefront of clinical research solutions.
Frequently Asked Questions
What is the Kit Inventory Portal (KIP)?
The Kit Inventory Portal (KIP) is a collaborative platform developed by Slope and CellCarta to streamline the ordering and management of clinical trial sample collection kits.
How does this collaboration benefit clinical trial sites?
This partnership simplifies inventory management, reduces waste, and enhances the efficiency of sample collection and logistics processes for clinical trial sites.
Who are the key players involved in this collaboration?
The key players are Slope, the biospecimen management platform, and CellCarta, a leading global contract research organization.
What impact does the partnership have on the pharmaceutical industry?
This collaboration aims to transform clinical logistics into a competitive advantage for pharmaceutical clients by providing innovative solutions that enhance operational efficiency.
How does Slope's platform improve clinical trial logistics?
Slope's platform offers features such as automated kit resupply, real-time inventory tracking, and customizable workflows, all of which enhance efficiency and reduce manual efforts.
